A randomized, multicenter, multicountry study to evaluate the effectiveness of Florbetapir (18F) PET imaging in changing patient management and to evaluate the relationship between Florbetapir (18F) PET status and cognitive decline.

Trial Profile

A randomized, multicenter, multicountry study to evaluate the effectiveness of Florbetapir (18F) PET imaging in changing patient management and to evaluate the relationship between Florbetapir (18F) PET status and cognitive decline.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Florbetapir F 18 (Primary)
  • Indications Alzheimer's disease; Dementia
  • Focus Diagnostic use
  • Sponsors Avid Radiopharmaceuticals
  • Most Recent Events

    • 22 Jul 2015 According to an Eli Lily media release, data from this study were presented today at the Alzheimer's Association International Conference 2015 (AAIC).
    • 22 Jul 2015 Results published in an Eli Lily media release.
    • 30 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top